Filanesib clinical trials
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2007
How each study uses filanesib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2007 (1)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2012 | 1 |
| 2015 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 2
Pfizer (2) · Array Biopharma, now a wholly owned subsidiary of Pfizer (2) · PETHEMA Foundation (1) · M.D. Anderson Cancer Center (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Antimitotic agents source
Studies
Open first, then newest update. How each study uses filanesib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) PatientsCompletedPhase 1/2PETHEMA FoundationNCT02384083Written as Filanesib, pomalidomide and dexamethasone
- A Study of ARRY-520 in Patients With Advanced Myeloid LeukemiaCompletedPhase 1/2PfizerNCT00637052Written as ARRY-520, KSP(Eg5) inhibitor; intravenous
- A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple MyelomaCompletedPhase 1/2PfizerNCT00821249Written as ARRY-520, KSP(Eg5) inhibitor; intravenous
- A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple MyelomaCompletedPhase 1Array Biopharma, now a wholly owned subsidiary of PfizerNCT01248923Written as ARRY-520, KSP(Eg5) inhibitor; intravenous
- A Study of ARRY-520 in Patients With Advanced CancerCompletedPhase 1Array Biopharma, now a wholly owned subsidiary of PfizerNCT00462358Written as ARRY-520, KSP(Eg5) inhibitor; intravenous
- Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell LeukemiaCompletedPhase 1M.D. Anderson Cancer CenterNCT01372540Written as Filanesib
Codes
What other systems call filanesib · ClinicalTrials.gg INT005509
- MeSH (NLM) C544550filanesibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 8A49OSO368FILANESIBConfirmed FDA, NLM, Wikidata
- Wikidata Q15634095filanesibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C68937FilanesibOne source FDA
- DrugBank DB06040One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C544550 | filanesib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 8A49OSO368 | FILANESIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q15634095 | filanesib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C68937 | Filanesib | One source FDA |
| DrugBank | DB06040 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.